QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NASDAQ:ACST

Acasti Pharma Stock Forecast, Price & News

Searched 734 Times  
$0.83
+0.10 (+13.62 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.77
Now: $0.83▼
$0.90
50-Day Range
$0.43
MA: $0.77▼
$1.20
52-Week Range
$0.17
Now: $0.83▼
$1.22
Volume35.08 million shs
Average Volume61.52 million shs
Market Capitalization$80.81 million
P/E RatioN/A
Dividend YieldN/A
Beta2.45
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Headlines

Acasti Pharma Announces Results for Third Quarter of Fiscal 2021
February 9, 2021 |  finance.yahoo.com
Making A List Of Penny Stocks Today? 4 Biotech Names To Watch
January 12, 2021 |  marketwatch.com
Acasti (ACST) Moves to Buy: Rationale Behind the Upgrade
December 25, 2020 |  finance.yahoo.com
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021
November 16, 2020 |  finance.yahoo.com
Here's Why Acasti Pharma (CVE:ACST) Must Use Its Cash Wisely
November 12, 2020 |  finance.yahoo.com
Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General By-Law and Other Related Matters Approved at Its AGM
October 22, 2020 |  finance.yahoo.com
Acasti announces initiation of strategic alternative process
September 29, 2020 |  seekingalpha.com
New finance chief at Acasti Pharma
September 16, 2020 |  seekingalpha.com
Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer
September 16, 2020 |  finance.yahoo.com
Acasti Pharma Stock Loses a Wall Street Supporter
September 1, 2020 |  finance.yahoo.com
Mid-Day Market Update: Akcea Therapeutics Jumps Following Acquisition News; Acasti Pharma Shares Plummet
August 31, 2020 |  benzinga.com
50 Stocks Moving In Monday's Mid-Day Session
August 31, 2020 |  msn.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACST
Previous Symbol
CUSIPN/A
CIK1444192
Webwww.acastipharma.com
Phone45-0686-4555
Employees32
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio3.66
Quick Ratio3.66

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.14 per share
Price / Book5.96

Profitability

EPS (Most Recent Fiscal Year)($0.23)
Net Income$-25,510,000.00
Net MarginsN/A
Return on Equity-342.52%
Return on Assets-112.03%

Miscellaneous

Outstanding Shares96,890,000
Market Cap$80.81 million
Next Earnings Date7/5/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.18 out of 5 stars

Medical Sector

852nd out of 1,958 stocks

Pharmaceutical Preparations Industry

424th out of 772 stocks

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.83
+0.10 (+13.62 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions

Is Acasti Pharma a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Acasti Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACST, but not buy additional shares or sell existing shares.
View analyst ratings for Acasti Pharma or view top-rated stocks.

What stocks does MarketBeat like better than Acasti Pharma?

Wall Street analysts have given Acasti Pharma a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acasti Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,590,000 shares, an increase of 428.2% from the December 31st total of 301,000 shares. Based on an average daily volume of 38,960,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 1.7% of the company's stock are short sold.
View Acasti Pharma's Short Interest.

When is Acasti Pharma's next earnings date?

Acasti Pharma is scheduled to release its next quarterly earnings announcement on Monday, July 5th 2021.
View our earnings forecast for Acasti Pharma.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) posted its quarterly earnings data on Thursday, August, 13th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01.
View Acasti Pharma's earnings history.

How has Acasti Pharma's stock been impacted by COVID-19 (Coronavirus)?

Acasti Pharma's stock was trading at $0.3849 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ACST shares have increased by 116.7% and is now trading at $0.8340.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ACST?

5 brokers have issued 1-year target prices for Acasti Pharma's shares. Their forecasts range from $0.50 to $7.00. On average, they expect Acasti Pharma's share price to reach $2.81 in the next year. This suggests a possible upside of 236.9% from the stock's current price.
View analysts' price targets for Acasti Pharma or view top-rated stocks among Wall Street analysts.

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the following people:
  • Ms. Janelle D' Alvise, Pres, CEO, Corp. Sec. & Director (Age 66, Pay $565.48k)
  • Dr. Pierre Lemieux, Co-Founder, COO & Chief Scientific Officer (Age 56, Pay $344.15k)
  • Mr. Brian D. Ford CPA, CA, Chief Financial Officer

Who are some of Acasti Pharma's key competitors?

Some companies that are related to Acasti Pharma include Onconova Therapeutics (ONTX), NextCure (NXTC), BELLUS Health (BLU), Galecto (GLTO), Sernova (SEOVF), Cerecor (CERC), Kamada (KMDA), Xeris Pharmaceuticals (XERS), Oncternal Therapeutics (ONCT), Tyme Technologies (TYME), Jaguar Health (JAGX), Galera Therapeutics (GRTX), MediciNova (MNOV), Oramed Pharmaceuticals (ORMP) and 9 Meters Biopharma (NMTR).
View all of ACST's competitors.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."

Who are Acasti Pharma's major shareholders?

Acasti Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.99%) and Oppenheimer & Co. Inc. (0.23%).
View institutional ownership trends for Acasti Pharma.

Which institutional investors are buying Acasti Pharma stock?

ACST stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Oppenheimer & Co. Inc..
View insider buying and selling activity for Acasti Pharma or or view top insider-buying stocks.

How do I buy shares of Acasti Pharma?

Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately $0.83.

How much money does Acasti Pharma make?

Acasti Pharma has a market capitalization of $80.81 million. The biopharmaceutical company earns $-25,510,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does Acasti Pharma have?

Acasti Pharma employs 32 workers across the globe.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is www.acastipharma.com.

Where are Acasti Pharma's headquarters?

Acasti Pharma is headquartered at 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 3009 BOUL. DE LA CONCORDE EAST SUITE 102, LAVAL A8, H7E 2B5. The biopharmaceutical company can be reached via phone at 45-0686-4555 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.